Stop TB Partnership

The Potential Impact of the COVID-19 Response on Tuberculosis in High-Burden Countries: A Modelling Analysis
May 1, 2020

World Health Organization (WHO)

Tuberculosis and COVID-19

April 4, 2020

Forbes

The Need To Avoid COVID-19 Stigma: Lessons From TB Response

April 1, 2020

The Union

COVID-19 and Lung Health: Frequently Asked Questions

March 25, 2020

Centers for Disease Control and Prevention

Tuberculosis and Public Health Emergencies

March 13, 2020

Oxford Immunotec

Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the COVID-19
January 23, 2020

The T-SPOT.TB test package insert

T-Cell Xtend® reagent package insert

Boarderline and Indeterminate result

News	VIEW ALL NEWS ›

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups 29 Apr 2021 VIEW MORE ›

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses 27 Apr 2021 VIEW MORE ›

Events

Interested in learning more about the T-SPOT.TB test and the TB markets we serve? Join us at any of these upcoming events

Moving Beyond the Tuberculin Skin Test (TST) (also known as the Mantoux Test)
Find out why this century-old test is no longer highly effective for the needs of the 21st century. Learn what the other options for TB screening are and the pros and cons of these different tests.

WATCH REPLAY

Expert Series: What is the Borderline? (Part 1)
Dr. Juzar Ali discusses the T-SPOT®.TB test’s Borderline result category and its clinical utility in helping to reduce the risk of misclassifying patients whose results are around the test’s established cut-offs for Positive or Negative. This video discusses the utility and significance of the T-SPOT.TB test’s Borderline result category.

WATCH REPLAY

Resources

Welcome!